Mesenchymal stem cells (MSCs) have emerged as a promising cellular vehicle for gene therapy of malignant gliomas due to their property of tumor tropism. However, MSCs may show bidirectional and divergent effects on tumor growth. Therefore, a robust surveillance system with a capacity for noninvasive monitoring of the homing, distribution and fate of stem cells in vivo is highly desired for developing stem cell-based gene therapies for tumors. In this study, we used ferritin gene-based magnetic resonance imaging (MRI) to track the tumor tropism of MSCs in a rat orthotopic xenograft model of malignant glioma. MSCs were transduced with lentiviral vectors expressing ferritin heavy chain (FTH) and enhanced green fluorescent protein (eGFP). Intra-arterial, intravenous and intertumoral injections of these FTH transgenic MSCs (FTH-MSCs) were performed in rats bearing intracranial orthotopic C6 gliomas. The FTH-MSCs were detected as hypointense signals on T2-and T2*-weighted images on a 3.0 T clinical MRI. After intra-arterial injection, 17% of FTH-MSCs migrated toward the tumor and gradually diffused throughout the orthotopic glioma. This dynamic process could be tracked in vivo by MRI up to 10 days of follow-up, as confirmed by histology. Moreover, the tumor tropism of MSCs showed no appreciable impact on the progression of the tumor. These results suggest that FTH reporter gene-based MRI can be used to reliably track the tropism and fate of MSCs after their systemic transplantation in orthotopic gliomas. This real-time in vivo tracking system will facilitate the future development of stem cell-based therapies for malignant gliomas.
Malignant gliomas account for 70% of primary malignant brain tumors in adult patients, and the incidence of this type of malignancy has recently increased. 1, 2 Despite advances in the standard-of-care treatment, 3 patients with malignant gliomas have a poor prognosis mainly due to the infiltrative and invasive growth pattern of the tumor cells, the limited delivery efficiency of chemotherapeutic agents due to the bloodbrain-tumor barrier (BBB) and accompanying dose-limiting systemic toxicities. 4 New therapies, such as gene and viral therapies, have shown promising but limited success, 5, 6 mainly due to the occurrence of host immune responses to therapeutic reagents or to the inefficient intratumor distribution of therapeutics. 6 Therefore, it is necessary to develop more effective therapeutic agents that can specifically target tumor cells while largely sparing normal cells and that can achieve widespread distribution throughout infiltrative lesions. Stem cells have emerged as attractive carriers for gene therapy of solid tumors due to their remarkable homing and migratory capacity of tumor tropism. 7 It was demonstrated that intracranially transplanted neural stem cells (NSCs) can migrate toward gliomas and deliver therapeutic agents to the gliomas even when the tumor foci are distant from the primary transplantation site. 8, 9 However, the use of NSCs is associated with difficulties in acquiring sufficient numbers of cells for use in therapy. Compared with NSCs, mesenchymal stem cells (MSCs) are an alternative candidate with a variety of clinical advantages. MSCs can be acquired from individual patients without raising ethical issues and can be autotransfused to avoid host immunoreactions, and they retain their stem cell characteristics and possess an extensive proliferative potential ex vivo. 10 Moreover, MSCs can cross the BBB to selectively and precisely target tumor cells after intravenous, 11 intra-arterial 12, 13 and intracranial injection. 14, 15 Tumor tropism capacity of this type is highly desirable for exploiting MSCs as a delivery vector for tumor treatment, especially in the case of malignant gliomas. Nonetheless, MSCs may show bidirectional and divergent effects on tumor growth that are highly dependent on their intricate and varying mutual interactions with tumor cells and with other stromal constituents in the tumor microenvironment. 16, 17 Hence, monitoring their biological behavior, including their migration, distribution, fate and therapeutic effects, in a real-time manner is very important in developing an effective MSCbased therapeutic strategy for gliomas.
Non-invasive magnetic resonance imaging (MRI) is a routine work-up in the clinical diagnosis and post-treatment surveillance of malignant gliomas. When cells are magnetically labeled, MRI can also be used to monitor the migration and homing of therapeutic stem cells in vivo. The most commonly used strategy for magnetic cell labeling involves the use of superparamagnetic iron oxide nanoparticles (SPIONs) to generate strong contrast and high sensitivity in MR images. 18, 19 This method has been used successfully to demonstrate the migration of MSCs to intracranial gliomas. 11, 20 Nevertheless, this strategy has several limitations, including progressive dilution of the contrast agent as cells divide 21 and false positive outcomes resulting from cell death. 22 The use of reporter gene-based MRI may overcome these shortcomings, since reporter genes are expressed only in viable cells and are expressed in a long-term manner. Ferritin is very suitable for reporter-gene MRI. 23 Overexpression of the ferritin heavy chain (FTH) alone can result in increased intracellular iron loading and produce robust signal contrast on T2-weighted (T2W) and/or T2*-weighted (T2*W) MR images. 24 To date, several different types of cells have been engineered to overexpress FTH and have been tracked by MRI in vivo. 23, 25, 26 However, little is known about the performance of ferritin reporter gene-based MRI in tracking the tropism of MSCs toward gliomas. Furthermore, the efficiency of migration and the distribution pattern, fate and influence on tumor growth of MSCs in gliomas remain unknown. In this study, we constructed a recombinant lentiviral vector expressing FTH and enhanced green fluorescent protein (eGFP) and used it to transduce MSCs. After intra-arterial injection of the MSCs, their migration and homing to an intracranial orthotopic xenograft glioma were tracked, and their effect on tumor growth was assessed using clinical 3.0 T MRI. The purpose of this study is to determine the performance of ferritin reporter gene-based MRI in in vivo tracking the tropism of MSCs toward gliomas and in determining the effect of MSCs on glioma growth.
Material and Methods

Cells
Rat MSCs and C6 glioma cells were obtained from Cyagen Bioscience Technology Co. (Guangzhou, China). MSCs and C6 cells were cultured at 378C under an atmosphere of 5% CO 2 in standard Dulbecco's Modified Eagle's Medium (DMEM; GIBCO, Grand Island, NY) containing 10% fetal bovine serum (FBS; GIBCO) and 1% glutamine (Sigma, St. Louis, MO) and in high-glucose DMEM (HG-DMEM, GIBCO) containing 10% FBS (Biological Industries, Beit Haemek, Israel), respectively; both media were supplemented with 1% penicillin/streptomycin (Sigma). MSCs that had undergone three to eight passages were used in the experiments.
Lentiviral vector construction and cell transduction
A lentiviral vector encoding rat FTH linked to eGFP was constructed and used to deliver reporter genes into MSCs (details of the viral vector construction are given in Supporting Information Methods). MSCs were transduced with the lentivirus encoding FTH and eGFP (FTH-MSCs) at a multiplicity of infection (MOI) of 10 for 24 hr and selected in medium with puromycin (2 lg/mL) for 1 week to yield FTH-MSCs. The expression of eGFP by FTH-MSCs was quantitatively assessed at 3 days and 10 days posttransduction using a FACSVerse flow cytometer (Becton Dickinson, Mountain View, CA). MSCs transduced with lentiviral vectors encoding only eGFP (eGFP-MSCs) were used as negative controls. Quantitative real-time PCR (qPCR) and Western blot analysis were performed to confirm the stable expression of FTH in selected clones.
qPCR and Western blot analysis qPCR and Western blot analysis of FTH-MSCs at 3, 10 and 15 days after transduction and of wild-type MSCs (WTWhat's new? Mesenchymal stem cells (MSCs) are promising vehicles for the delivery of therapeutic agents to brain tumors, due in part to their tumor homing and migratory capabilities. Noninvasive tools to monitor their movement and fate in vivo, however, are needed. In this study, MSC migration toward gliomas and the effects of MSCs on glioma growth were tracked using a ferritin reporter gene-based magnetic resonance imaging strategy. About 17% of MSCs were observed migrating and diffusing throughout orthotopic gliomas in rats following intra-arterial delivery. MSC tropism had no obvious effects on tumor progression.
MSCs) at similar passages were performed. For qPCR, total RNA was extracted from 1 3 10 6 FTH-MSCs and 1 3 10 6 WT-MSCs using the RNAiso Plus reagent (Takara Bio, Shiga, Japan), according to the manufacturer's protocol. After the concentration of total RNA in the extract was measured, cDNA was synthesized using PrimeScript TM RT Master Mix Kit (Takara). The sequences of the primers used in cDNA synthesis are provided in Supporting Information Table 1 . SYBR Green qPCR SuperMix (Life Technologies, Carlsbad, CA)-based qPCR was performed using a PRISMV R 7500 Sequence Detection System (Applied Biosystems, Foster City, CA). All data were analyzed using the 2 -DDCT method, and target mRNA levels were normalized to those of GAPDH, which served as an internal control. For Western blot analysis, 1 3 10 6 FTH-MSCs and 1 3 10 6 WT-MSCs were lysed in radioimmunoprecipitation assay (RIPA; Thermo Fisher Scientific Inc., Rockford, IL) buffer containing a protease inhibitor cocktail (Thermo Fisher Scientific). Proteins of interest were visualized using the Immobilon Western Chemiluminescent Detection Reagents and chemiluminescence system (EMD Millipore, Temecula, CA). Additional details regarding Western blot analysis are presented in the Methods section of the Supporting Information.
Cellular iron accumulation
To determine the effect of transduction with the lentivirus encoding FTH and eGFP on cellular iron accumulation, Prussian blue staining and transmission electron microscopy (TEM) were used to qualitatively assess iron accumulation in FTH-MSCs. For Prussian blue staining, FTH-MSCs and WTMSCs were cultured in 6-well plates at 2 3 10 5 cells per well in standard medium with or without ferric citrate (FC, 200 lmol/L; Sigma). After 72 hr of incubation, the cells were fixed and incubated in a solution of 10% hydrochloride acid and 10% potassium ferrocyanide (II) trihydrate for 30 min at 378C. The proportion of positive cells was quantified by counting the number of blue-stained cells in each group using the measurement tool in Image Pro-Plus software (Image Pro-Plus 6.0; Media Cybernetics, Silver Spring, MD). For TEM, 1 3 10 6 FTH-MSCs and 1 3 10 6 WT-MSCs treated with 200 lmol/L FC were centrifuged and fixed in 2.5% glutaraldehyde cacodylate buffer at 48C overnight. After incubation in 1% OsO4 for 1 hr, the cells were dehydrated and embedded in artificial resin (Epon; Merck, Darmstadt, Germany). Ultrathin sections were cut, stained with uranyl acetate and lead citrate and imaged using a H-7650 TEM (Hitachi, Tokyo, Japan) at 80-120 kV.
The effect of transduction on cellular iron accumulation was further quantitatively determined by in vitro MRI and atomic absorption spectrometry (AAS). Briefly, 2 3 10 Table 2 . After MRI, the cells were suspended in 1 M HCl solution to cause the thorough release and dissolution of iron, and the iron content was quantified by AAS (Z-200, Hitachi). To further assess the effect of gene transduction on imaging in the absence of supplementation with FC, FTH-MSCs were incubated with 200 lmol/L FC for 72 hr; the medium was then discarded, and the cells were washed three times with PBS to eliminate residual FC. After culturing of the cells under standard culture conditions for an additional 0, 2, 4, 6, or 10 days, 2 3 10 6 FTH-MSCs were collected, and in vitro MRI was performed to assess the T2 signal intensity and T2 value of the FTH-MSCs.
In vitro cytotoxicity
To evaluate whether viral transduction and FTH overexpression are detrimental to cells, the viability, apoptosis rate, level of intracellular reactive oxygen species (ROS), phenotype, multi-lineage differential potential and migratory capability of the cells were assessed. The cell viability and apoptosis rate in WT-MSCs, eGFP-MSCs and FTH-MSCs were assessed using the Cell Counting Kit-8 (CCK-8, Dojindo Laboratories, Kumamoto, Japan) assay and the annexin V-APC/ propidium iodide (PI) double-staining method, respectively, as previously described. 19, 27 Cell viability was expressed as the percentage of viable cells relative to WT-MSCs. The ROS assay kit (Genmed, Shanghai, China) was used to measure intracellular ROS production in the absence and presence of iron supplementation. Briefly, WT-MSCs, eGFP-MSCs and FTH-MSCs were treated with or without 200 lmol/L FC for 72 hr; the cells were then collected and resuspended in 1000 lL of diluent buffer containing 1 mmol/L dihydroethidium (DHE). After incubation at 378C for 20 min, the cells were centrifuged, suspended and examined using a FACSVerse flow cytometer (Becton Dickinson). The presence of an increased level of intracellular ROS was marked by a rightward peak in the phycoerythrin (PE) fluorescent wave. The ROS production results are reported as the geometric mean fluorescence (Geo-means).
The phenotype of FTH-MSCs was characterized by fluorescence-activated cell sorting (FACS) analysis of cell surface markers. Briefly, FTH-MSCs were labeled with PE, V450 and Alexa Fluor 647-conjugated monoclonal antibodies against CD90, CD29 and CD45, respectively, for 30 min (1:10; BD Biosciences, San Jose, CA). The expression of cell surface markers was then assessed using a FACSVerse cytometer (Becton Dickinson). To evaluate the differentiation potential of the cells, WT-MSCs, eGFP-MSCs and FTHMSCs were cultured using three different mesenchymal differentiation kits (Cyagen) for 2-3 weeks to induce osteogenic, adipogenic and chondrogenic differentiation. The cells were then stained with alizarin red to detect osteogenic differentiation, with Oil Red O to detect adipogenic differentiation, and with alcian blue to detect chondrogenic differentiation. The transwell migration assay was used to evaluate the effects of
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transduction and FTH overexpression on the ability of MSCs to migrate toward glioma cells (see details in Supporting Information Methods).
Animals and orthotopic glioma model
Adult male Wistar rats weighing 220-250 g were purchased from the Laboratory Animal Center of Guangzhou University of Chinese Medicine (Guangzhou, China). All experimental procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health and were approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University (Guangzhou, China). The animals were housed in a standard animal facility and allowed standard food and water ad libitum.
To establish the orthotopic glioma model, rats were anesthetized by intraperitoneal injection (i.p.) of pentobarbital sodium (40 mg per 1000 g body weight; Sigma), and 5 3 10 5 C6 cells were stereotaxically injected into the left striatum (coordinates: 1 mm rostral and 3 mm lateral to the bregma, at 5 mm depth from the pial surface) of each animal using a Hamilton 32-G eedle connected to a 10-lL syringe (Hamilton Company, Reno, NV). Establishment of the intracranial glioma model was confirmed by MRI seven days after inoculation of tumor cells.
Cell transplantation
At Day 8 post-inoculation, when intracranial tumors had reached 4-6 mm in diameter, fifty animals were randomly assigned to five groups (n 5 10 in each group) and subjected to intra-arterial injection of 2 3 10 6 FTH-MSCs (FTH-MSC group), intra-arterial injection of 2 3 10 6 eGFP-MSCs (eGFP-MSC group), intra-arterial injection of the same volume of PBS (PBS group), intravenous injection of 2 3 10 6 FTH-MSCs (i.v. FTH-MSC group) and intratumoral injection of 2 3 10 6 FTH-MSCs (i.t. FTH-MSC group). Intra-arterial injection was performed via the ipsilateral internal carotid artery as previously reported. 12, 28 Intratumoral injection was performed via stereotactic injection, and intravenous injection was performed via the tail vein (see details in Supporting Information Methods). Prior to injection, FTH-MSCs were grown in 200 lmol/L FC-supplemented medium for 72 hr. At 7, 8, 10, 12, 14, and 18 days after tumor inoculation, which corresponded to the time points before injection of MSCs, immediately after injection of MSCs, and 2, 4, 6, and 10 days after injection of MSCs, respectively, in vivo MRI was performed.
To determine the potential tropism of MSCs to damaged brain areas, five healthy rats were intra-arterially injected with 2 3 10 6 FTH-MSCs 1 day after a brain wound was created in the left striatum using a needle (26-G, Hamilton) puncture. In vivo MRI was performed immediately after needle puncture (Day 0) and 1 (Day 1), 3 (Day 3), 5 (Day 5), 7 (Day 7) and 9 days (Day 9) after cell injection. Three days after cell injection (Day 3), 2 animals chosen at random were sacrificed, and their brains were harvested for immunohistochemical staining for FTH. To determine the localization of FTH-MSCs within the tumor, six additional animals received stereotactic injections of fluorescent C6 cells to establish the orthotopic glioma model. The C6 cells were pre-labeled with the fluorescent dye CM-DiI (Molecular Probes, Eugene, OR), according to the manufacturer's protocol. These animals then received intra-arterial (n 5 2), intravenous (n 5 2) or intratumoral injection (n 5 2) of 2 3 10 6 FTH-MSCs.
In vivo MRI
In vivo MRI was performed using a clinical 3.0 T system (Intera; Philips Medical Systems) with a 50 mm 3 50 mm 4-channel phased array rat coil (Suzhou Medcoil Healthcare Co., Ltd, Suzhou, China). Axial and coronal brain T2W and T2*W images were obtained. The imaging sequences and acquisition parameters are provided in Supporting Information Table 3 . To observe the homing and migration of FTHMSCs toward the glioma, the hypointense signal areas were observed on T2*W images from animals in the FTH-MSC, eGFP-MSC, PBS, i.v. FTH-MSC and i.t. FTH-MSC groups.
Tumor growth and survival analysis
To evaluate the influence of injected MSCs on tumor growth, the tumor volume in the FTH-MSC, eGFP-MSC, PBS, i.v. FTH-MSC and i.t. FTH-MSC groups was measured 7, 8, 10, 12, 14, 18 days after tumor inoculation. On T2W images, the hyperintense tumor region was manually outlined using ImageJ software (National Institutes of Health, Bethesda, MD). The hyperintense areas on all image slices were summed to generate the tumor volume. To observe the effect of treatment with MSCs on animal survival, 24 additional animals with orthotopic gliomas were randomized into four groups (n 5 6 in each group); the animals in these groups received intratumoral injection, intra-arterial injection or intravenous injection of 2 3 10 6 FTH-MSCs or intra-arterial injection of PBS. The survival time was observed, and the survival curve was estimated using the method of Kaplan and Meier.
Histology
At 8, 12 and 18 days after tumor inoculation, two animals in each of the FTH-MSC, eGFP-MSC and PBS groups were randomly sacrificed, and their brains were cryosectioned into serial coronal 10-lm-thick slices as previously described. 19 Hematoxylin and eosin (H&E) staining, Prussian blue staining, immunohistochemical staining for FTH and CD11b and immunofluorescence staining for eGFP were performed to detect the homing, migration and fate of intra-arterially administered MSCs (see details in Supporting Information Methods). To determine whether FTH-MSCs become entrapped or migrate to extracranial major organs, at 0 days and 7 days after injection of FTH-MSCs (Day 8 and Day 15 post-inoculation), the lung, liver, spleen, kidney, coeliac lymph node and bone of two animals in the FTH-MSC group were harvested, and sections of these organs were processed for HE staining, Prussian blue staining and immunohistochemical staining for FTH. Moreover, animals with orthotopic CM-DiI-labeled gliomas were sacrificed 2 days after injection of MSCs, and their brains were removed. Frozen sections were obtained and analyzed by fluorescence microscopy (LSM 710; Carl Zeiss, Jena, Germany).
Ex vivo fluorescence imaging
To evaluate the efficiency with which intra-arterially and intravenously injected MSCs reached the tumors, a quantification method based on fluorescence imaging was performed as described previously. 29, 30 Briefly, the fluorescence intensities of different numbers (1 3 10 5 to 1 3 10 7 ) of FTH-MSCs were determined using the in vivo imaging system (Xenogen IVIS spectrum; Caliper Life Sciences, Hopkinton, MA). The fluorescence signals were quantified using Living Image 4.0 software (Xenogen) to establish a standard calibration curve. Immediately after injection, animals that had received intraarterial injection or intravenous injection of 2 3 10 6 FTHMSCs (n 5 3 in each group) were sacrificed. The left hemisphere was dissected and assessed by fluorescence imaging. Three animals bearing gliomas received no cell injections and served as controls. The fluorescence signals were quantified, and the number of FTH-MSCs reaching the tumor was determined according to the pre-established calibration curve.
Ex vivo qPCR
To elucidate the fate of FTH-MSCs after their arrival at the tumor, the mRNA expression level of the eGFP gene was determined by qPCR. Briefly, nine additional animals with intracranial gliomas that had received intra-arterial injections of 2 3 10 6 FTH-MSCs were sacrificed 0, 4 or 10 days after the injections (n 5 3 at each time point). The left hemispheres with orthotopic gliomas were collected for qPCR analysis. Animals with intracranial gliomas but without injection of FTH-MSCs (n 5 3) served as controls.
Iron supplementation after FTH-MSC injection
To determine the effect of systemic iron administration on the detection of surviving FTH-MSCs, nine additional animals with intracranial gliomas were randomly assigned to three groups (n 5 3 in each group); the groups received intra-arterial injections of 2 3 10 6 FTH-MSCs, 2 3 10 6 eGFP-MSCs or PBS, respectively. Following the intra-arterial injection, all of the animals in the three groups received intraperitoneal injections of iron dextran as previously reported. 31 Three days later (on Day 6 after MSC injection), in vivo MRI and ex vivo fluorescence imaging were performed (see details in Supporting Information Methods).
Statistical analysis
The data are presented as mean 6 SD. Comparisons of mRNA and protein levels, cell viability, apoptosis rate, intracellular ROS level, T2 value, iron concentration and migration rate were performed using one-way analysis of variance (ANOVA). The tumor volume was analyzed by repeated measures analysis of variances. A log-rank (MantelCox) test was used to determine the p values for KaplanMeier survival analyses. Statistical analysis was performed using SPSS 13.0 software (SPSS Inc.; Chicago, IL). p < 0.05 was considered to indicate a significant difference.
Results
FTH expression in MSCs
The lentiviral vector was successfully constructed and used to express FTH and eGFP proteins (Fig. 1a) . Strong expression of eGFP was observed in FTH-MSCs under fluorescence microscopy (Supporting Information Fig. S1 ), with a transduction efficiency of 89% at 3 days after transduction. After selection with puromycin for 7 days, the measured transduction efficiency was >95% (Fig. 1b) . qPCR and Western blot assays confirmed the increased expression of FTH in FTHMSCs (Figs. 1c and 1d ). FTH expression increased in a timedependent manner between 3 and 15 days after transduction (Figs. 1d and 1e) .
Cellular iron accumulation
Prussian blue staining showed abundant blue-stained particles within the cytosol and nuclei of FTH-MSCs that had been treated with FC (Fig. 2a) . In FTH-MSCs that were not treated with FC, only a few blue particles were evident in the cytosol of a small fraction of the cells. In FTH-MSCs treated with and without FC, the percentages of positively stained cells were 80 and 9%, respectively. No blue-stained particles were found in WT-MSCs either with or without iron supplementation. TEM revealed accumulations of dark electrondense iron particles in the cytoplasmic vacuoles of FTHMSCs treated with FC, whereas no such iron accumulation was seen in WT-MSCs (Fig. 2b) . Treatment with FC substantially increased the iron storage capacity of FTH-MSCs but not that of eGFP-MSCs or WT-MSCs, as indicated by a noticeable decrease in signal intensity on T2W and T2*W images (Fig. 2c) and a decrease in T2 values (Fig. 2d) in cells that received FC treatment. Further quantitative AAS confirmed a marked increase in the iron content (3.61 6 0.65 pg per cell) of FTH-MSCs that received FC treatment (Fig. 2e) . These findings indicate that both FTH overexpression and an adequate iron supply are needed for the production of an appreciable signal contrast in the cells of interest on a clinical MR scanner. As shown in Figures 2f and 2g , the low signal intensity of FTH-MSCs on T2W and T2*W images gradually recovered after withdrawal of iron supplementation. Correspondingly, the T2 values of the cells gradually increased.
In vitro cytotoxicity
The cell viabilities and apoptosis rates of WT-MSCs, eGFPMSCs and FTH-MSCs and the ROS levels in WT-MSCs, eGFP-MSCs and FTH-MSCs that did not receive FC treatment did not differ significantly (p > 0.05). The level of ROS
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was significantly increased in WT-MSCs and eGFP-MSCs, but not in FTH-MSCs, after treatment with FC for 72 hr (Fig. 3a) , demonstrating the protective effect of overexpression of FTH against FC toxicity. FTH-MSCs remained strongly positive for the surface markers CD90 (99.07%) and CD29 (99.80%) and negative for CD45 (1.8%) (Fig. 3b) . WT-MSCs, eGFP-MSCs and FTH-MSCs showed similar capacities for multi-lineage differentiation into osteocytes, adipocytes and chondrocytes when cultured in appropriate induction media (Fig. 3c) ; thus, FTH transduction did not alter the differentiation potential of MSCs. The transwell migration assay showed that, in comparison with serum-free medium, conditioned medium from C6 cells triggered remarkable migration of FTH-MSCs in a pattern similar to the migration of WT-MSCs and eGFP-MSCs (Figs. 3d and  3e) . Thus, rat glioma cells were able to trigger the tropism of MSCs in vitro, and the migratory capability of MSCs was not altered by lentiviral transduction.
In vivo MRI
The orthotopic glioma manifested as a mass with hyperintense signal on T2W images (Fig. 4a) . FTH-MSCs were detected as a circular hypointense signal in the core of tumors immediately after intra-arterial injection (Day 8 postinoculation) on T2W (Fig. 4a) and T2*W images (Fig. 4b) . Between 2 and 6 days after injection (Days 10-14 post-inoculation), the hypointense signals representing FTH-MSCs gradually dispersed within the tumors. The magnitude of the hypointense signal gradually decreased, and the signal had almost disappeared at 10 days after injection (Day 18 postinoculation). These results suggest that FTH-MSCs specifically migrated to and accumulated within the tumors. Intratumoral injection of FTH-MSCs resulted in an immediate obvious hypointense signal within the tumor on T2W and T2*W images (Supporting Information Fig. S2) ; this signal showed a similar pattern of change in intensity as the signal 
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observed following intra-arterial injection of FTH-MSCs. In contrast, animals that received intravenous injections of FTH-MSC had no observable hypointense signal in the tumor on T2W and T2*W images during the entire study period (Supporting Information Fig. S2 ). No hypointense signals representing FTH-MSCs were found in proximity to the 
Effects of MSCs on tumor growth and animal survival
The tumor volumes in animals treated with FTH-MSCs (via intra-arterial, intratumoral and intravenous injection), eGFPMSCs and PBS all increased rapidly with time. No significant differences were found in the tumor growth patterns in the five experimental groups (p > 0.05) (Supporting Information Fig. S4A ), indicating that the homing and migration of MSCs did not have an appreciable effect on tumor progression during the short period of the study. In addition, the survival times of animals treated with FTH-MSCs by various routes of administration were not significantly different from the survival times of animals treated with PBS (p > 0.05) (Supporting Information Fig. S4B ). These findings indicate that MSCs did not promote or inhibit tumor progression after their arrival in gliomas regardless of whether they were locally or systemically delivered.
Histology
HE staining showed no necrosis or hemorrhage in the tumors in the FTH-MSC, eGFP-MSC and PBS groups. Immunohistochemical staining for FTH and Prussian blue staining showed numerous FTH-positive and blue-stained FTH-MSCs scattered within the tumor immediately after intra-arterial injection. Thereafter, the injected cells dispersed throughout the tumor and appeared to decrease in quantity. By 10 days after injection, FTH-positive, blue-stained FTHMSCs were seen along the border of the tumor. Immunohistochemical staining for FTH and immunofluorescence staining for eGFP showed well-matched distributions of FTHMSCs (Fig. 5a) . No FTH-MSCs migrated away from the tumor site to the adjacent normal brain tissue. The distribution of FTH-MSCs was spatially consistent with the distribution indicated by in vivo MRI. eGFP-MSCs exhibited migration and distribution patterns similar to those of FTHMSCs, as detected by immunofluorescence staining for eGFP (Fig. 5b) . Immunohistochemical staining for the microgliaspecific antigen CD11b and Prussian blue staining showed that CD11b-positive cells and blue-stained cells were barely co-localized (Fig. 5c) , findings indicative of the survival of FTH-MSCs. In addition, FTH-MSCs were found within the tumor interstitium but did not fuse with tumor cells (Supporting Information Fig. S5 ). Furthermore, HE staining and immunochemical staining for FTH showed normal appearance of the major extracranial organs, and no FTH-MSCs were found in these organs (Supporting Information Fig. S6 ).
Ex vivo fluorescence imaging
The fluorescence intensity of eGFP in FTH-MSCs increased as the cell number increased (Fig. 6a) . According to the standard cell number-fluorescence intensity curve (Fig. 6b) , 17 6 6% of the injected FTH-MSCs arrived in the tumor immediately after intra-arterial injection (Fig. 6c) , whereas no fluorescence signals were detected in the tumor immediately after intravenous injection of FTH-MSCs.
Ex vivo qPCR
The results of the ex vivo qPCR assays showed that eGFP gene expression decreased gradually in animals that received intra-arterial injections of FTH-MSCs during the period from immediately after injection (Day 8 post-inoculation) to 10 days after injection (Day 18 post-inoculation), but it remained slightly higher than normal (Fig. 6d) . This finding suggests that the injected FTH-MSCs gradually died after their arrival in the tumor.
Iron supplementation after FTH-MSC injection
Iron supplementation resulted in the presence of a strong hypointense MRI signal in and around the tumors in animals treated with FTH-MSCs, eGFP-MSCs or PBS. Although the presence of FTH-MSCs could not be clearly discerned based on their typical hypointense signal, ex vivo fluorescence imaging confirmed the arrival of MSCs in the tumor (Supporting Information Fig. S7 ).
Discussion
In this study, a lentiviral vector was used to efficiently transduce MSCs and cause them to overexpress FTH; this resulted in enhanced intracellular iron storage. Transduction of ferritin expression did not alter the viability, apoptosis rate, multi-lineage differentiation potential, phenotype or migration capacity of the cells. When pre-conditioned by exposure to iron supplementation, the transgenic MSCs generated remarkable signal contrast on both in vitro and in vivo MRI. A small fraction of the injected MSCs arrived in the tumors, and the tropism of MSCs toward the orthotopic gliomas could be reliably tracked by MRI after intra-arterial delivery of the cells. Moreover, the accumulation of MSCs showed no appreciable impact on tumor progression or on animal survival during the short period of the study.
MRI is an attractive choice for monitoring the survival and trafficking of transplanted stem cells in real time. 21 Previous studies have suggested that ferritin reporter gene-based MRI can be successfully used to visualize superficially located glioma xenografts. 24, 25 In the present study, we constructed a lentiviral vector and used it to successfully transfer FTH into MSCs. FTH overexpression can enhance the iron storage capacity of transduced cells, resulting in appreciable dark signals on T2W and T2*W images on a clinical MR scanner. Previous studies reported that FTH-overexpressing cells supplemented with various concentrations of FC showed increased iron content ranging from 0.72 pg/cell 32 to 7.766 pg/cell. 31 In this study, after culture of FTH-MSCs in the presence of 200 lmol/L FC, the average intracellular iron content was 3.61 pg/cell. The difference between our results and the previously reported results may be related to differences in the viral vector system, the promoter, the type of transduced cells and the concentration of FC used. Nevertheless, the iron content of the cells in our study was less than that of cells directly labeled with SPIONs (9.214 6 1.466 pg per cell). 27 Hence, the sensitivity of FTH-based MRI imaging remains to be improved, in particular for analysis of cells on a clinical MR scanner.
The safety of introducing a reporter gene has been a longstanding concern in genetic manipulation of stem cells. Our study showed that overexpression of FTH in MSCs had no detrimental effect on cell viability, apoptosis, differentiation capacity or surface phenotype. Another concern is that excess accumulation of ferrous ions (Fe 21 ) in cells may have adverse effects because Fe 21 facilitates the generation of oxidative stress, leading to damage to cellular constituents. 33 The Hsubunit of ferritin is considered an anti-apoptotic factor because its ferroxidase activity promotes the oxidation of Fe 21 to Fe 31 followed by sequestration of excess intracellular iron within the ferritin molecules. [33] [34] [35] Our study showed that the supplementation with FC at a low dose (200 lmol/ L) increased ROS production in cells without FTH expression but that it did not increase ROS production in FTHoverexpressing MSCs. Therefore, consistent with the results of previous studies, 25, 36 overexpression of FTH may protect transduced cells against ROS. It is well known that the majority of cellular ferritin is located in the cytosol. 33 During certain stages of cell development or in the presence of surplus amounts of cellular iron and pro-inflammatory cytokines, ferritin is transiently transported into the nucleus, where it protects DNA from oxidative damage. 37 
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Stem cell-based therapy is emerging as an attractive strategy to combat cancer. 7 Previous studies have demonstrated that locally or systemically administered MSCs show inherent tropism for gliomas and that these cells can "trail" aggressive tumor cells. 12, 15, 38 Nonetheless, determination of the dynamics of MSCs in these studies relied entirely on postmortem histology. In vivo tracking of the dynamics of MSCs in the tumor microenvironment is required for reliable utilization of stem cells for cancer therapy. In this study, FTH-based MRI was used to monitor the in vivo trafficking of MSCs in orthotopic gliomas. Our results showed that ferritin overexpression had no detrimental effect on cell migration capacity; the transgenic MSCs showed clear tropism toward the tumor and arrived in the tumor immediately after intra-arterial injection.
In the present study, the in vivo tropism of MSCs toward intracranial gliomas was longitudinally and noninvasively visualized using MRI. Our results showed that MSCs were initially located in the core of the tumor and that they then diffused throughout the tumor and reached its periphery. Histology confirmed the distribution and migration pattern of MSCs revealed by MRI. Despite the fact that the histological distributions of FTH-positive cells and iron deposits did not precisely match, the iron particles were consistently found in FTH-MSCs rather than in microglia. Therefore, we speculate that some FTH-overexpressing cells had not absorbed sufficient iron prior to injection and after their arrival in the tumor, resulting in negative Prussian blue staining. Systemic supplementation of iron after FTH-MSCs injection seems useful for circumventing this problem. However, our results showed that intraperitoneal injection of iron after FTH-MSC injection resulted in a strong hypointense signal in tumors that hampered the observation of FTH-MSCs. Disruption of the BBB at the tumor site might result in increased accumulation of iron in the tumor, which would produce a strong hypointense signal. Thus, systemic administration of iron seems not to be a feasible strategy for measuring the survival of FTH-MSCs on MRI. Notably, the tropism of MSCs to gliomas could be tracked by MRI for up to 10 days because the hypointense signal of MSCs only gradually declined with time. The results of ex vivo qPCR assays suggested that the observed decay of the hypointense signal resulted from the gradual death of MSCs after their arrival in the glioma. Thus, reporter gene-based MRI may make it possible not only to track the tumor tropism of MSCs but also to determine the actual survival of MSCs. These advantages remedy the major shortcomings associated with the use of a direct labeling strategy such as SPION. In addition, our data showed that 17% of injected FTH-MSCs arrived in the tumor immediately after intra-arterial injection. The relatively small number of FTH-MSCs within the tumor might explain why a less obvious hypointense signal was detected in FTHMSCs by in vivo MRI than by in vitro MRI.
It is widely recognized that MSCs can migrate to sites of cerebral injury and ischemia and to tumor microenvironments. 10 In our study, an experimental wound was inflicted on the brain parenchyma by needle puncture. No infiltration of the wound site by FTH-expressing MSCs was detected either by MRI or by histology. A similar phenomenon was observed in another study; in that study, no NSCs were found to migrate toward the site in which a needle was inserted to mimic tissue damage. 8 However, intracerebrally or intravenously injected MSCs were found to migrate toward regions of extensively damaged brain tissue in a traumatic brain contusion injury. 39 Therefore, minor central nervous system destruction alone does not prompt the dramatic migration of MSCs. 8 Because the signals to which the MSCs respond most likely consist of a "mixture" of attractants, adhesion and substrate molecules and chemokines, 8 the lack of infiltration of the experimentally inflicted wound by MSCs might be associated with inadequate release of tropic cytokines by the damaged normal tissue in this circumstance.
Due to their transdifferentiation capability and their complex interactions with tumor cells and tumor-associated stromal cells, MSCs grafted into tumors are implicated in almost all the features acknowledged as hallmarks of cancer, including tumor proliferation, immunomodulation, angiogenesis and metastasis. 16, 40 The role that MSCs play in tumor progression is paradoxical because they can either promote or inhibit tumor growth. These illusive features may be attributed to several factors, including the heterogeneity of MSCs, host status, differences in tumor models, and even the dose and timing of MSC administration. 41 In our study, no remarkable effects of MSCs on tumor growth or animal survival were observed in a 10-day follow-up. This might be associated with the relatively small number of MSCs (17%) that arrived in the tumor after a single intra-arterial injection; this number of cells may have been insufficient to influence the progression of the tumor. The administration route can directly affect the efficacy of stem-cell-based treatment. 42 In our study, intratumoral injection of FTH-MSCs delivered a large quantity of cells into tumors, but it enhances the risk of brain injury 43, 44 and might result in considerable MRI signal voids. In previous studies, stem cells delivered by intravenous injection were entrapped in lungs due to the pulmonary first pass effect.
12, 45 Our results showed that only a few FTHMSCs arrived in the tumor after intravenous injection. Comparatively, intra-arterial injection is more favorable because it can bypass the pulmonary circulation 28 and makes invasive surgical intervention unnecessary. 12 In addition, intra-arterial delivery can be readily realized clinically through percutaneous transfemoral catheterization of selected intracranial arteries. 46 Our study has several limitations. First, although lentivirus-mediated overexpression of FTH in stem cells yields relatively high labeling efficiency, it generates less clearly appreciable contrast on a clinical MR scanner without pre-conditioning of the cells with iron supplementation. The use of higher-performance MRI is expected to increase the detection sensitivity of FTH-based imaging. Second, only one glioma model, the C6 cell line, was investigated in our study. Future studies using additional models such as glioblastoma models are highly warranted to confirm the tropism of MSCs found in the C6 glioma model. Third, the exact mechanism underlying the tumor tropism of MSCs was not explored in our study. Previously, the molecular mechanism of tumor tropism has been partially explained. 11, 15, 20, 47, 48 It was shown that MSCs can migrate into gliomas through tumor blood vessels, 13 a process that is likely driven by active angiogenesis, 11 and that the MSCs then act as pericytes within the tumors. 15 In addition, MSCs may sense signaling molecules, such as SDF-1, 20 macrophage migration inhibitory factor, 47 and matrix metalloproteinase-2, 48 which are released from tumor tissues, preferentially retained at tumor sites and gradually incorporated into the tumor microenvironment. Finally, the effect of MSCs on tumor growth was assessed over a relatively short period of time. Further work is required to elucidate the mutual interactions between different constituents of the tumor microenvironment and exogenous MSCs, as well as to determine the long-term effect of MSCs on tumor progression.
In summary, our study results demonstrated that a fraction of intra-arterially administered MSCs migrate to intracranial gliomas, followed by diffusion within the tumor and massive cell death. The dynamics of homing, migration and distribution of MSCs could be clearly visualized by FTHbased MRI. Thus, ferritin reporter gene-based MRI can be used to reliably track the tropism and fate of MSCs after systemic transplantation of these cells into orthotopic gliomas. This real-time, noninvasive imaging tracking system will facilitate the future development of stem cell-based therapies for malignant gliomas.
